Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our Alzheimer’s disease research aims to cross the divide between basic genomic research, translational research, prevention and clinical care.  Our research spans:

Molecular mechanisms

  • Genetic research has been an important pillar of our understanding of the molecular pathology of Alzheimer’s disease. 
  • Our research is based on big data analysis aiming to discover new genetic variants, and determine their functional effects using induced pluripotent stem cells, iPSCs.
  • We study biomarkers and their clinical implications using multi-omics studies at the Big Data Institute (BDI) and Nuffield Dept of Population Health (NDPH).

 From genes to medication

  • The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) bridges the gap between molecular mechanisms underlying Alzheimer disease and development of innovative drugs.
  • The center combines state of art drug discovery expertise with that of researchers from Genetics, Biology, Chemistry, Psychiatry, and Neuroscience.

 Cognition and Neuroimaging

  • Our expertise in brain imaging at the Wellcome Centre for Integrative Neuroimaging (WIN) has led to novel methods to analyse brain structure and function and how these are disrupted in Alzheimer’s disease.
  • We have developed new, sensitive ways to measure memory in people with Alzheimer’s (Cognitive Neurology).

 Cohorts and epidemiology

 Clinical and patient-focused research

  • We are part of the Oxford NIHR Biomedical Research Centre (Oxford BRC) and the Oxford Health HIHR Biomedical Research Centre (Oxford Health BRC).
  • Our team at the Dept of Psychiatry are leading figures in European Prevention of Alzheimer’s Dementia (EPAD) longitudinal cohort study, deep and Frequent Phenotyping (DFP) and MIcroglial CSF1R in Alzheimer’s Disease (MICAD) studies. They are conducting experimental research on biomarkers and leading clinical trials in dementia.
  • Our Cognitive Disorders Clinic at the John Radcliffe Hospital, Brain Health Centre at the Warneford Hospital and memory clinic services provide high-quality assessments for patients, integrating research into clinical services.